Vitality Watch

Dossier pubmed preclinical 09-nov-2026
Animal model, organoid, or cell-culture result — not yet human

α-Ketoglutarate Promotes Hepatic Steatosis by Enhancing Cidec Stability via Lactylation-Ubiquitination Crosstalk.

Key claim: Long-term dietary supplementation with α-ketoglutarate induces hepatic steatosis in healthy mice by stabilizing Cidec and suppressing adipose triglyceride lipase activity.

Abstract

α-Ketoglutarate (AKG), a key tricarboxylic acid cycle intermediate, is widely consumed as a dietary supplement by healthy individuals for its perceived anti-aging and performance-enhancing benefits. While its antidiabetic and anti-obesity effects have been reported under pathological conditions, the safety profile and mechanisms of long-term AKG intake in healthy animals remain largely unexplored. Here, we demonstrate that long-term AKG intake via food or drinking water markedly elevates hepatic triglyceride levels and induces steatosis in healthy mice by suppressing adipose triglyceride lipase (Atgl) activity. The lipid-droplet-associated protein, cell death-inducing DNA fragmentation factor 45-like effector C (Cidec), is an inhibitor of Atgl. We find that AKG stabilizes Cidec by attenuating tripartite-motif protein 21-mediated ubiquitination. Mechanistically, AKG reduces H3K4me3 at thepromoter, activatingtranscription, which promotes lactate production and subsequent Cidec lactylation. This lactylation inhibits Cidec ubiquitination, restrains Atgl activity, and ultimately drives hepatic triglyceride accumulation. Hepatocyte-specific knockdown oformarkedly ameliorates AKG-induced steatosis. Collectively, our findings reveal that long-term AKG intake enhances Cidec stability through a phosphoenolpyruvate carboxykinase 1- and tripartite-motif protein 21-mediated “lactylation-ubiquitination crosstalk”, thereby inhibiting Atgl activity and contributing to hepatic steatosis in mice. These results caution that even AKG with established health benefits may pose a risk of liver injury when used chronically in healthy mice.

Why this matters

[animal-model] Chronic AKG supplementation produced hepatic steatosis in healthy mice, adding an adverse liver outcome to the evidence record for this longevity supplement. This finding challenges assumptions of uniformly beneficial effects, but does not establish human liver risk; enthusiasm for long-term human use exceeds what this preclinical study can resolve.

Source

Link

Briefing card

α-Ketoglutarate Promotes Hepatic Steatosis by Enhancing Cidec Stability via Lactylation-Ubiquitination Crosstalk.
Stage: preclinical · pubmed · 09-nov-2026

If you take AKG for longevity, this study raises a liver-safety question based on healthy mice, not demonstrated harm in humans.

Long-term dietary supplementation with α-ketoglutarate induces hepatic steatosis in healthy mice by stabilizing Cidec and suppressing adipose triglyceride lipase activity.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.34133/research.1471

build build 880 · 2bcef25 · 2026-11-18